



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Phenobarbital (injection), Phenytoin/Phenobarbital, Phenytoin/Phenobarbital/Caffeine and Sodium Benzoate, Phenobarbital Sodium (injection)

March 21, 2017

Non-proprietary name

Phenobarbital (injection), Phenytoin/Phenobarbital, Phenytoin/Phenobarbital/Caffeine and Sodium Benzoate, and Phenobarbital Sodium (injection)

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection regarding dependence of the Adverse Reactions section, the following text should be revised (underlined parts are revised):

Dependence: Drug dependence may occur due to prolonged use. Patients should be carefully monitored and caution should be exercised for dosage and treatment duration when administering this drug. In addition, withdrawal symptoms such as anxiety, insomnia, convulsions, nausea, hallucinations, delusions, excitement, confusion, or depressed state may occur due to rapid dose reduction or discontinuation of this drug during prolonged use. Discontinuation of administration should be carefully carried out such as by gradual dose reduction.

* These drugs are designated as a drug requiring preparation of a Drug Guide for Patients.